Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 to the Retinal Pigment Epithelium (RPE) [AAV2-hRPE65v2-301]

NCT00999609 is registered in ClinicalTrials.gov with Spark Therapeutics, Inc. as lead sponsor.

NCT NCT00999609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00999609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 to the Retinal Pigment Epithelium (RPE) [AAV2-hRPE65v2-301]
Lead sponsor
Spark Therapeutics, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 31, 2012
Completion date
January 31, 2030
Enrollment
31 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

inherited retinal dystrophy due to rpe65 mutations, leber congenital amaurosis